Description

Product details

SAMIGLUTIDE 4 MG is a semaglutide-containing injectable medicine supplied in a pre-filled pen. The stated formulation contains 4 mg of semaglutide in 3 mL of solution, corresponding to approximately 1.34 mg/mL. Semaglutide is a GLP-1 receptor agonist that acts on physiological pathways involved in blood-glucose control, appetite, and gastrointestinal function. Its use should be based on the approved indication for the specific product and the advice of a qualified healthcare professional. Product Overview Product: SAMIGLUTIDE 4 MG Active substance: Semaglutide Strength: 4 mg/3 mL Approximate concentration: 1.34 mg/mL Dosage form: Injectable solution Presentation: Pre-filled pen Route: Subcutaneous administration, according to the applicable product instructions The 4 mg/3 mL concentration is also associated with certain approved semaglutide products. However, this does not mean that their dosing schedules, indications, or administration instructions automatically apply to SAMIGLUTIDE 4 MG. The product-specific labeling should always be followed. What Is Semaglutide? Semaglutide is a medication belonging to the GLP-1 receptor agonist class. It acts similarly to the naturally occurring hormone glucagon-like peptide-1 (GLP-1). GLP-1 is involved in several processes related to metabolism. Its activity can influence insulin secretion, glucagon regulation, stomach emptying, and appetite. Depending on the particular semaglutide product and its regulatory authorization, semaglutide may be prescribed for conditions such as type 2 diabetes or chronic weight management in appropriately selected patients. Because different semaglutide products can have different approved uses and formulations, treatment decisions should be based on the specific medicine being prescribed. SAMIGLUTIDE 4 MG Pre-Filled Pen SAMIGLUTIDE 4 MG is supplied in a pre-filled pen intended to provide a convenient format for subcutaneous administration. Pre-filled devices can eliminate the need to draw medication from a conventional vial. Nevertheless, patients should be properly trained before using an injectable pen and should follow the instructions supplied with the specific product. The pen should only be used according to its approved instructions, including the prescribed dose and administration schedule. Strength and Formulation Each stated 3 mL presentation contains 4 mg of semaglutide, giving a concentration of approximately 1.34 mg/mL. The concentration of a medicine should not be confused with the amount delivered in every injection. The quantity administered depends on the design and dose settings of the particular pen. For this reason, patients should not calculate or select their own dose based solely on the concentration printed on the package. The prescribed dose should come from the product's authorized instructions and the treating healthcare professional. How Semaglutide Acts Semaglutide activates GLP-1 receptors, which are involved in the regulation of blood glucose and appetite. Among its physiological effects, GLP-1 receptor activation can: Support glucose-dependent insulin secretion. Reduce inappropriate glucagon secretion when blood glucose is elevated. Affect gastrointestinal activity, including gastric emptying. Influence appetite and food intake. The overall response to treatment can vary between individuals and depends on factors such as the medical indication, prescribed dose, treatment duration, and other medicines being used. Potential Therapeutic Benefits When prescribed for an appropriate, authorized indication, semaglutide may form part of a broader treatment program. For eligible individuals with type 2 diabetes, certain approved semaglutide medicines are used to improve glycemic control. Other approved semaglutide formulations have indications involving chronic weight management for qualifying patients. Medication should be considered alongside the broader treatment strategy recommended by a healthcare professional, which may include nutritional management, physical activity, glucose monitoring, and other appropriate interventions. Possible Side Effects Like other prescription medicines, semaglutide can cause unwanted effects. Frequently reported gastrointestinal reactions associated with semaglutide products include: Nausea Vomiting Diarrhea Constipation Abdominal discomfort or pain Not every patient experiences these effects, and their severity can vary. Semaglutide products also have important safety considerations. Depending on the specific approved product, labeling includes warnings concerning conditions such as pancreatitis, gallbladder-related problems, severe gastrointestinal reactions, kidney problems associated with dehydration, and serious hypersensitivity reactions. Patients should provide their healthcare professional with a complete medical history before treatment begins. Important Contraindications and Warnings Certain semaglutide products carry a contraindication for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious hypersensitivity to semaglutide or an applicable component is also an important contraindication. The exact warnings and contraindications applicable to SAMIGLUTIDE 4 MG should be confirmed against its current authorized product information in the relevant country. Patients should seek professional medical advice if they develop concerning symptoms during treatment. Correct Administration SAMIGLUTIDE 4 MG should be administered only according to the prescription and instructions applicable to the product. Before using a pre-filled pen, patients should receive appropriate instruction regarding: Dose selection Injection technique Injection sites Pen operation Storage Disposal of used needles or injection equipment The dose or frequency should never be changed independently. A pre-filled injection pen should not be shared with another person, even if a new needle is attached. Sharing injectable medication devices can create a risk of transmitting infections and is contrary to appropriate safe-use practices. Storage Storage requirements should be determined from the official SAMIGLUTIDE 4 MG packaging and product information supplied with the medicine. Patients should not rely on storage instructions from a different semaglutide brand because formulations, devices, and stability requirements can differ between products. Use by Healthcare Professionals Healthcare professionals should assess whether SAMIGLUTIDE 4 MG is appropriate for an individual patient by considering the relevant diagnosis, treatment objectives, medical history, contraindications, concurrent medicines, and applicable regulatory requirements. Particular attention should be given to the distinction between different semaglutide products. Although they contain the same active ingredient, products may differ in: Approved indications Concentration Pen design Dose increments Administration schedules Storage conditions Regulatory labeling The product-specific prescribing information should therefore be consulted before treatment is initiated or adjusted. Advantages of a Pre-Filled Pen A pre-filled pen can provide a practical method of administering an injectable medicine. Compared with a conventional vial-and-syringe presentation, the device may reduce some preparation steps and can be convenient for patients who have been appropriately trained. Convenience, however, should not take precedence over product authenticity, regulatory approval, correct dosing, proper storage, and professional medical supervision. SAMIGLUTIDE 4 MG: Key Points SAMIGLUTIDE 4 MG is described as a semaglutide injection containing 4 mg in 3 mL, supplied in a pre-filled pen. The most important considerations are: Semaglutide is a GLP-1 receptor agonist. The stated formulation is 4 mg/3 mL (approximately 1.34 mg/mL). Administration is by the subcutaneous route when prescribed for that route. The appropriate dose and frequency must come from the product-specific instructions and prescription. Dosing information from another semaglutide brand should not automatically be applied. Patients should be informed about possible adverse reactions and relevant contraindications. The pen must not be shared between patients. Storage and handling should follow the official product information. Treatment should be supervised by an appropriately qualified healthcare professional. Frequently Asked Questions What is SAMIGLUTIDE 4 MG? SAMIGLUTIDE 4 MG is a semaglutide-containing injectable formulation described as 4 mg/3 mL, supplied in a pre-filled pen. Its approved use depends on the regulatory authorization applicable to the product and market. What does 4 mg/3 mL mean? It indicates that the stated 3 mL presentation contains a total of 4 mg of semaglutide, equivalent to approximately 1.34 mg of semaglutide per mL. This concentration alone should not be used to determine an individual's injection dose. Is SAMIGLUTIDE 4 MG a prescription medicine? Semaglutide medicines are prescription products in many jurisdictions. SAMIGLUTIDE 4 MG should be used only in accordance with applicable regulations, authorized product information, and professional medical advice. How is SAMIGLUTIDE 4 MG administered? The product is described as a subcutaneous injection. However, the exact dose, injection frequency, and pen operation should be determined from the SAMIGLUTIDE 4 MG product information and the patient's prescription. Can SAMIGLUTIDE 4 MG be taken together with another semaglutide medicine? Patients should not combine semaglutide-containing medicines or switch between them without medical supervision. Some approved semaglutide labels specifically advise against combining their product with another semaglutide-containing medicine or another GLP-1 receptor agonist. Can the dose be changed without consulting a doctor? No. Patients should not increase, decrease, or otherwise modify the prescribed dose or injection schedule without guidance from their healthcare professional. Conclusion SAMIGLUTIDE 4 MG – Semaglutide Injection 4 mg/3 mL (approximately 1.34 mg/mL) Pre-Filled Pen is a semaglutide-based injectable formulation designed for subcutaneous use according to its applicable product instructions. Because semaglutide products can vary substantially in their approved indications, concentrations, devices, and dosing regimens, information from another semaglutide product should not be assumed to apply to SAMIGLUTIDE 4 MG. For appropriate and safe use, patients and healthcare professionals should rely on the current official product information, local regulatory authorization, and individualized medical advice. Any questions concerning suitability, dosing, interactions, contraindications, or adverse effects should be discussed with a qualified healthcare professional.

Other Specifications